The sales are routine in size relative to market cap and follow a major acquisition close — likely driven by post-deal portfolio rebalancing rather than fundamental concern. Monitor for any additional insider sales in the next 30 days; a sustained pattern would warrant closer attention. The acquisition integration and debt service remain the key catalysts.
Price Chart
Executive Summary
Two Neurocrine insiders sold a combined $38.43M in shares over the past week, with Director Kevin Gorman accounting for $37.82M (245.1K shares at $154.33) and the Chief Corporate Affairs Officer selling $609K. The sales follow the May 18 closing of the $2.9B Soleno Therapeutics acquisition, which added $600M in new debt. At 0.24% of market cap ($15.7B), the total sell value is modest and likely reflects portfolio rebalancing or tax planning post-deal, not a bearish signal on the business.
Key Financial Metrics
Key Facts
- Director Kevin Gorman sold 245,100 shares for $37.82M on May 19, 2026.
- Chief Corp. Affairs Officer David Boyer sold 3,888 shares for $609K on May 26, 2026.
- Total insider sales of $38.43M represent ~0.24% of NBIX's $15.7B market cap.
- Sales occurred within 10 days of closing the $2.9B Soleno Therapeutics acquisition, funded in part with $600M in new debt.
- No open-market purchases were reported in the cluster.
Financial Impact
Insider sales of $38.43M, or 0.24% of market cap — below the 0.5% materiality threshold.
Risk Factors
- Post-acquisition integration risk for Soleno's VYKAT XR could pressure near-term earnings.
- Additional $600M in debt increases leverage, though the revolving credit facility provides flexibility.
- Further insider selling without purchases could signal waning confidence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NBIX-1780006230820 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $149.50 $139.49 | ▼ −6.70% | ▼ −9.26% | $143.18 (−4.23%) |
Jul 13, 2026 11w ago | Insider Cluster | $174.10 $170.88 | ▼ −1.85% | ▼ −1.06% | $143.18 (−17.76%) |
Jul 9, 2026 12w ago | Press Release | $177.11 $171.55 | ▼ −3.14% | ▼ −2.58% | $143.18 (−19.16%) |
Jun 9, 2026 16w ago | Insider Cluster | $160.86 $156.42 | ▼ −2.76% | ▼ −6.19% | $143.18 (−10.99%) |
Jun 8, 2026 16w ago | Insider Cluster | $165.24 $159.51 | ▼ −3.47% | ▼ −5.88% | $143.18 (−13.35%) |
Jun 8, 2026 16w ago | Insider Cluster | $165.24 $159.51 | ▼ −3.47% | ▼ −5.88% | $143.18 (−13.35%) |
Jun 4, 2026 17w ago | Insider Cluster | $163.88 $159.76 | ▼ −2.51% | ▼ −3.08% | $143.18 (−12.63%) |
Jun 2, 2026 17w ago | Insider Cluster | $164.23 $160.86 | ▼ −2.05% | ▲ +1.77% | $143.18 (−12.81%) |
Jun 2, 2026 17w ago | Insider Cluster | $164.23 $160.86 | ▼ −2.05% | ▲ +1.77% | $143.18 (−12.81%) |
Jun 2, 2026 17w ago | Insider Cluster | $164.23 $160.86 | ▼ −2.05% | ▲ +1.77% | $143.18 (−12.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access